Accéder au contenu
Merck

Opioid-induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment.

PloS one (2014-10-11)
Celine Duraffourd, Erica Kumala, Laura Anselmi, Nicholas C Brecha, Catia Sternini
RÉSUMÉ

Opioids, acting at μ opioid receptors, are commonly used for pain management. Chronic opioid treatment induces cellular adaptations, which trigger long-term side effects, including constipation mediated by enteric neurons. We tested the hypothesis that chronic opioid treatment induces alterations of μ opioid receptor signaling in enteric neurons, which are likely to serve as mechanisms underlying opioid-induced constipation. In cultured rat enteric neurons, either untreated (naïve) or exposed to morphine for 4 days (chronic), we compared the effect of morphine and DAMGO (D-Ala2,MePhe4,Gly-ol5 enkephalin) on μ opioid receptor internalization and downstream signaling by examining the activation of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2 (MAPK/ERK) pathway, cAMP accumulation and transcription factor cAMP Response Element-Binding protein (CREB) expression. μ opioid receptor internalization and MAPK/ERK phosphorylation were induced by DAMGO, but not morphine in naïve neurons, and by both opioids in chronic neurons. MAPK/ERK activation was prevented by the receptor antagonist naloxone, by blocking receptor trafficking with hypertonic sucrose, dynamin inhibitor, or neuronal transfection with mutated dynamin, and by MAPK inhibitor. Morphine and DAMGO inhibited cAMP in naïve and chronic enteric neurons, and induced desensitization of cAMP signaling. Chronic morphine treatment suppressed desensitization of cAMP and MAPK signaling, increased CREB phosphorylation through a MAPK/ERK pathway and induced delays of gastrointestinal transit, which was prevented by MAPK/ERK blockade. This study showed that opioids induce endocytosis- and dynamin-dependent MAPK/ERK activation in enteric neurons and that chronic morphine treatment triggers changes at the receptor level and downstream signaling resulting in MAPK/ERK-dependent CREB activation. Blockade of this signaling pathway prevents the development of gastrointestinal motility impairment induced by chronic morphine treatment. These findings suggest that alterations in μ opioid receptor downstream signaling including MAPK/ERK pathway in enteric neurons chronically treated with morphine contribute to the development of opioid-induced constipation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Saccharose, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Saccharose, ≥99.5% (GC)
Sigma-Aldrich
Saccharose, ≥99.5% (GC), BioXtra
Sigma-Aldrich
Saccharose, BioUltra, for molecular biology, ≥99.5% (HPLC)
USP
Saccharose, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Saccharose, ≥99.5% (GC), BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Saccharose, ≥99.5% (GC)
Sigma-Aldrich
Saccharose, ≥99.5% (GC), Grade II, suitable for plant cell culture
Supelco
Saccharose, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Saccharose, Grade I, ≥99% (GC), suitable for plant cell culture
USP
Naloxone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Saccharose, meets USP testing specifications
Supelco
Meprobamate solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Saccharose, ACS reagent
Sigma-Aldrich
Saccharose, puriss., meets analytical specification of Ph. Eur., BP, NF
Millipore
Saccharose, suitable for microbiology, ACS reagent, ≥99.0%
Supelco
Saccharose, analytical standard, for enzymatic assay kit SCA20
Saccharose, European Pharmacopoeia (EP) Reference Standard
Supelco
Meprobamate, analytical standard